US · Healthcare · Medical Devices
EPS came in at 0.47 against a street estimate of -0.12 — a beat of 491.7%.
Analysts rate Glaukos Corp a strong buy (12 buy, 1 hold, 0 sell out of 13) with an average price target of $242.46.
CONFIDENT Record sales and strong Epioxa and iDose adoption drove a raised 2026 outlook. Management sees $1 billion revenue in 2027 despite potential iDose coverage changes. Q3 FY26 U.S. growth was led by Epioxa and iDose TR; international glaucoma growth remained broad-based at 15% constant currency. Analysts focused on Epioxa’s launch mechanics, iDose LCD risk, margins and 2027 growth. Management emphasized strong site and payer expansion while withholding detailed product-level forecasts and timing. 2026-10-28…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 16.12% |
| Jupiter Topco LLC | 8.21% |
| Vanguard Portfolio Management, LLC | 5.61% |
| PRIMECAP Management Company | 5.14% |
| Vanguard Capital Management, LLC | 4.31% |
| State Street Corp | 3.91% |
| Millennium Management LLC | 2.67% |
| Holocene Advisors, LP | 2.56% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 net sales were $211,030 thousand, up from $133,537 thousand in the third quarter of 2025. • Nine-month 2026 ne | 2026-10-28 |
| Results announced · Q4 2026 HEADLINE NUMBERS • 3Q 2026 revenue was $211.0 million, up 58% on both a reported and constant-currency basis versus 3Q 2025. • Non-GAAP gross margin | 2026-10-28 |
| Reg FD disclosure · Q3 2026 GLAUKOS CORPORATION (GKOS) - 8-K FILING SUMMARY HEADLINE NUMBERS • Filing Date: August 3, 2026 • Company: Glaukos Corporation, Delaware incorporatio | 2026-08-03 |
| Quarterly report · Q2 2026 GLAUKOS CORPORATION - 10-Q SUMMARY (Q2 2026) HEADLINE NUMBERS • Net Sales (6 months ended June 30, 2026): $336.2 million vs. $230.8 million in prior | 2026-07-29 |
| Results announced · Q3 2026 GLAUKOS CORPORATION (GKOS) – Q2 2026 SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Q2 2026 revenue: $185.6 million, up 50% year-over-year (49% con | 2026-07-29 |
| Shareholder vote results · Q2 2026 GLAUKOS CORPORATION - 8-K SUMMARY HEADLINE NUMBERS • Annual stockholder meeting held May 28, 2026 • Total votes cast across proposals: approximately | 2026-06-03 |
| Reg FD disclosure · Q2 2026 GLAUKOS CORPORATION (GKOS) - 8-K SUMMARY HEADLINE NUMBERS • Filing Date: May 4, 2026 • Company: Glaukos Corporation, Delaware incorporated • Stock T | 2026-05-04 |
| Quarterly report · Q1 2026 GLAUKOS CORPORATION - 10-Q SUMMARY Q1 2026 (Quarter Ended March 31, 2026) --- HEADLINE NUMBERS • Net sales: $150.6 million (Q1 2026) vs. $106.7 mil | 2026-04-30 |
Readable in the app.
| Announcement | Date |
|---|---|
| Raised 2026 net sales guidance and introduced preliminary 2027 net sales guidance Glaukos reported a very strong third quarter ended September 30, 2026. Revenue reached a record $211.0 million, up 58% from $133.5 million a year earlier, driven by U.S. Glaucoma sales of $1 | 2026-10-28 |
| Raised 2026 net sales guidance to $680-700 million from $620-635 million Glaukos Corporation reported exceptional Q2 2026 results that exceeded expectations. Net sales reached a record $185.6 million, representing 50% year-over-year growth. Glaucoma-specific sale | 2026-07-29 |
| Raises 2026 net sales guidance to $620-635 million from $600-620 million Glaukos, an eye disease treatment company, reported strong Q1 2026 results that exceeded expectations. Key highlights: Record quarterly sales of $150.6 million, up 41% year-over-year (39% ad | 2026-04-29 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Glaukos Corp — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.